Ocular Hypertension: Drug Development Pipeline Study, H1 2018
Ocular Hypertension pipeline comprises of 27 drugs under development as of March 2018. Of these, 2 drugs are in Phase 1 and 13 drugs in phase 2 and 6 drugs in Phase 3. Further, 5 drugs remain in Pre-clinical stage. One drug is in pre-registration stage.
20 companies are developing the pipeline for Ocular Hypertension. Of this, Santen Pharmaceutical Co Ltd and NicOx SA have largest number of compounds in pipeline. Mechanism of Action of most of the therapeutic candidates is Prostaglandin E EP2 receptor agonist.
Ocular Hypertension is a condition where, InterOcular Pressure (IOP) is more than the maximum limit of 21 mmHg in one or both the eyes with older population largely affected by the condition. The pressure increase is observed without any observed optic nerve damage or vision loss.
If untreated, the disease can evolve into glaucoma and can also lead to permanent vision loss. In specific, African and Caribbean population is more susceptible to Ocular Hypertention compared to Europeans. Further, the condition is more common among nearsighted and diabetic patients.
The pressure increase is observed typically because of aqueous humor or drainage problems, which results in fluid buildup, resulting in elevated eye pressure.
The most comprehensive pipeline review “Ocular Hypertension- Drug Development Pipeline Study” provides in-depth analysis and update information on Ocular Hypertension pipeline drugs. Current status of all the drugs in the Ocular Hypertension pipeline is provided in the research work.
The report provides detailed analysis of Ocular Hypertension pipeline including companies involved, drugs in different stages of development, drug development details across regions (Region (North America, Europe, Asia Pacific and Rest of the World). Further, the Ocular Hypertension report identifies aspects important in modifying industry market scenarios, increasing opportunities and list of potential companies that impact the Ocular Hypertension industry.
Scope:
20 companies are developing the pipeline for Ocular Hypertension. Of this, Santen Pharmaceutical Co Ltd and NicOx SA have largest number of compounds in pipeline. Mechanism of Action of most of the therapeutic candidates is Prostaglandin E EP2 receptor agonist.
Ocular Hypertension is a condition where, InterOcular Pressure (IOP) is more than the maximum limit of 21 mmHg in one or both the eyes with older population largely affected by the condition. The pressure increase is observed without any observed optic nerve damage or vision loss.
If untreated, the disease can evolve into glaucoma and can also lead to permanent vision loss. In specific, African and Caribbean population is more susceptible to Ocular Hypertention compared to Europeans. Further, the condition is more common among nearsighted and diabetic patients.
The pressure increase is observed typically because of aqueous humor or drainage problems, which results in fluid buildup, resulting in elevated eye pressure.
The most comprehensive pipeline review “Ocular Hypertension- Drug Development Pipeline Study” provides in-depth analysis and update information on Ocular Hypertension pipeline drugs. Current status of all the drugs in the Ocular Hypertension pipeline is provided in the research work.
The report provides detailed analysis of Ocular Hypertension pipeline including companies involved, drugs in different stages of development, drug development details across regions (Region (North America, Europe, Asia Pacific and Rest of the World). Further, the Ocular Hypertension report identifies aspects important in modifying industry market scenarios, increasing opportunities and list of potential companies that impact the Ocular Hypertension industry.
Scope:
- - All latest industry developments and their impact on projects and companies
- - Complete overview of global Ocular Hypertension therapy options and treatments
- - The pipeline study reviews drug details for Ocular Hypertension by developing companies, institutions, mechanism of action, Target, Route, Phase (pre-clinical/ Discovery, Phase 1, Phase 2, Phase 3, Pre-Registration, IND/ NDA), molecule
- - Mergers, Acquisitions, licensing, co-development and project acquisition news for Ocular Hypertension market
- - Ocular Hypertension drugs being developed in combination with other drugs are also detailed
- - Company wise drugs listed with their current status, partners and news updates
1 TABLE OF CONTENTS
1.1 LIST OF FIGURES
1.2 LIST OF TABLES
2 EXECUTIVE SUMMARY
2.1 DISEASE OVERVIEW
2.2 PIPELINE SNAPSHOT
2.3 PIPELINE DRUGS BY PHASE
2.4 PIPELINE DRUGS BY COMPANY
2.5 PIPELINE DRUGS BY MECHANISM OF ACTION
3 OCULAR HYPERTENSION- COMPANY WISE PIPELINE ANALYSIS
3.1 AERIE PHARMACEUTICALS, INC PIPELINE, H1 2018
3.2 ALCON LABORATORIES INC PIPELINE, H1 2018
3.3 ALLERGAN PLC PIPELINE, H1 2018
3.4 CAN-FITE BIOPHARMA LTD PIPELINE, H1 2018
3.5 D. WESTERN THERAPEUTICS INSTITUTE INC PIPELINE, H1 2018
3.6 ENVISIA THERAPEUTICS INC PIPELINE, H1 2018
3.7 F. HOFFMANN-LA ROCHE LTD PIPELINE, H1 2018
3.8 IRONWOOD PHARMACEUTICALS INC PIPELINE, H1 2018
3.9 LABORATORIOS SOPHIA S.A. DE C.V PIPELINE, H1 2018
3.10 MATI THERAPEUTICS INC PIPELINE, H1 2018
3.11 NEURIM PHARMACEUTICALS LTD PIPELINE, H1 2018
3.12 NICOX SA PIPELINE, H1 2018
3.13 OCULAR THERAPEUTIX INC PIPELINE, H1 2018
3.14 PEREGRINE OPHTHALMIC PIPELINE, H1 2018
3.15 SANTEN PHARMACEUTICAL CO LTD PIPELINE, H1 2018
3.16 SENJU PHARMACEUTICAL CO.,LTD PIPELINE, H1 2018
3.17 SHIRE PLC PIPELINE, H1 2018
3.18 SYLENTIS SAU PIPELINE, H1 2018
3.19 TAEJOON PHARMACEUTICAL CO., LTD. PIPELINE, H1 2018
3.20 VISCI LTD. PIPELINE, H1 2018
4 OCULAR HYPERTENSION DRUG SNAPSHOTS
4.1 ROCLATAN DRUG DETAILS
4.1.1 Snapshot-
4.1.2 Drug Overview-
4.1.3 Mechanism of Action-
4.1.4 Current Status-
4.1.5 Phase 3 Details
4.1.6 Trial details include-
4.2 MGV354 DRUG DETAILS
4.2.1 Snapshot-
4.2.2 Drug Overview
4.2.3 Mechanism of Action
4.2.4 Current Status
4.3 BIMATOPROST OCULAR INSERT
4.3.1 Snapshot-
4.3.2 Drug overview
4.3.3 Mechanism of Action
4.3.4 Phase 1/ 2 trial details
4.4 CF 101 DRUG DETAILS
4.4.1 Snapshot-
4.4.2 Drug Overview
4.4.3 Mechanism of Action
4.4.4 Current Status
4.4.5 Trial Details
4.5 WP-1303 DRUG DETAILS
4.5.1 Snapshot-
4.5.2 Drug Overview
4.5.3 Mechanism of Action
4.5.4 Current Status
4.5.5 Trial Details
4.6 ENV515 DRUG DETAILS
4.6.1 Snapshot-
4.6.2 Drug Overview
4.6.3 Mechanism of Action
4.6.4 Current Status
4.6.5 Trial Details
4.7 RG 7945- DRUG DETAILS
4.7.1 Snapshot-
4.7.2 Drug Overview
4.7.3 Mechanism of Action
4.7.4 Current Status
4.7.5 Phase 1 trial details
4.8 IWP 953 DRUG DETAILS
4.8.1 Snapshot-
4.8.2 Drug Overview
4.8.3 Mechanism of Action
4.8.4 Current Status
4.8.5 Trial details
4.9 SOPH067 DRUG DETAILS
4.9.1 Snapshot-
4.9.2 Drug Overview
4.9.3 Mechanism of Action
4.9.4 Current Status
4.9.5 Phase 3 Trial details
4.10 PRO-122 DRUG DETAILS
4.10.1 Snapshot-
4.10.2 Drug Overview
4.10.3 Mechanism of Action
4.10.4 Current Status
4.10.5 Trial details
4.11 PIROMELATINE DRUG DETAILS
4.11.1 Snapshot-
4.11.2 Drug Overview
4.11.3 Mechanism of Action
4.11.4 Current Status
4.11.5 Trial details
4.12 NCX 470 DRUG DETAILS
4.12.1 Snapshot-
4.12.2 Drug Overview
4.12.3 Mechanism of Action
4.12.4 Current Status
4.12.5 Trial Details
4.13 NCX 667 DRUG DETAILS
4.13.1 Snapshot-
4.13.2 Drug Overview
4.13.3 Mechanism of Action
4.13.4 Current Status
4.13.5 Trial details
4.14 NCX 1653 DRUG DETAILS
4.14.1 Snapshot-
4.14.2 Drug Overview
4.14.3 Mechanism of Action
4.14.4 Current Status
4.15 OTX-TP DRUG DETAILS
4.15.1 Snapshot-
4.15.2 Drug Overview
4.15.3 Mechanism of Action
4.15.4 Current Status
4.15.5 Trial details
4.16 OTX-TIC DRUG DETAILS
4.16.1 Snapshot-
4.16.2 Drug Overview
4.16.3 Mechanism of Action
4.16.4 Current Status
4.16.5 Trial Details
4.17 DE-117 DRUG DETAILS
4.17.1 Snapshot-
4.17.2 Drug Overview
4.17.3 Mechanism of Action
4.17.4 Current Status
4.17.5 Trial details
4.18 DE 126 DRUG DETAILS
4.18.1 Snapshot-
4.18.2 Drug Overview
4.18.3 Mechanism of Action
4.18.4 Current Status
4.18.5 Trial details
4.19 DE-130A DRUG DETAILS
4.19.1 Snapshot-
4.19.2 Drug Overview
4.19.3 Mechanism of Action
4.19.4 Current Status
4.20 Y-39983 DRUG DETAILS
4.20.1 Snapshot-
4.20.2 Drug Overview
4.20.3 Mechanism of Action
4.20.4 Current Status
4.20.5 Trial details
4.21 SJP 0135 DRUG DETAILS
4.21.1 Snapshot-
4.21.2 Drug Overview
4.21.3 Mechanism of Action
4.21.4 Current Status
4.21.5 Trial details
4.22 SHP 639 DRUG DETAILS
4.22.1 Snapshot-
4.22.2 Drug Overview
4.22.3 Mechanism of Action
4.22.4 Current Status
4.22.5 Trial details
4.23 BAMOSIRAN DRUG DETAILS
4.23.1 Snapshot-
4.23.2 Drug Overview
4.23.3 Mechanism of Action
4.23.4 Current Status
4.23.5 Trial details
4.24 LATANOPROST-PPDS DRUG DETAILS
4.24.1 Snapshot-
4.24.2 Drug Overview
4.24.3 Mechanism of Action
4.24.4 Current Status
4.24.5 Trial Details
4.25 VS 101 DRUG DETAILS
4.25.1 Snapshot-
4.25.2 Drug Overview
4.25.3 Mechanism of Action
4.25.4 Current Status
4.26 LIPOSOMAL LATANOPROST DRUG DETAILS
4.26.1 Snapshot-
4.26.2 Drug Overview
4.26.3 Mechanism of Action
4.26.4 Current Status
4.26.5 Trial details
4.27 TJO 002 DRUG DETAILS
4.27.1 Snapshot-
4.27.2 Drug Overview
4.27.3 Current status
4.27.4 Trial details
5 RECENT DEVELOPMENTS IN OCULAR HYPERTENSION PIPELINE
5.1 FDA APPROVES LATANOPROSTENE BUNOD OPHTHALMIC SOLUTION 0.024% - NOVEMBER 2017
5.2 DAILY USE OF STEROID DROPS INCREASES RISK FOR OCULAR HYPERTENSION - JULY 2017
5.3 NICOX PROVIDES CLINICAL AND REGULATORY UPDATE FOR NCX 470 FOR IOP LOWERING- JANUARY 2017
6 APPENDIX
6.1 ABOUT VPA RESEARCH
6.2 SOURCES AND RESEARCH METHODOLOGY
1.1 LIST OF FIGURES
1.2 LIST OF TABLES
2 EXECUTIVE SUMMARY
2.1 DISEASE OVERVIEW
2.2 PIPELINE SNAPSHOT
2.3 PIPELINE DRUGS BY PHASE
2.4 PIPELINE DRUGS BY COMPANY
2.5 PIPELINE DRUGS BY MECHANISM OF ACTION
3 OCULAR HYPERTENSION- COMPANY WISE PIPELINE ANALYSIS
3.1 AERIE PHARMACEUTICALS, INC PIPELINE, H1 2018
3.2 ALCON LABORATORIES INC PIPELINE, H1 2018
3.3 ALLERGAN PLC PIPELINE, H1 2018
3.4 CAN-FITE BIOPHARMA LTD PIPELINE, H1 2018
3.5 D. WESTERN THERAPEUTICS INSTITUTE INC PIPELINE, H1 2018
3.6 ENVISIA THERAPEUTICS INC PIPELINE, H1 2018
3.7 F. HOFFMANN-LA ROCHE LTD PIPELINE, H1 2018
3.8 IRONWOOD PHARMACEUTICALS INC PIPELINE, H1 2018
3.9 LABORATORIOS SOPHIA S.A. DE C.V PIPELINE, H1 2018
3.10 MATI THERAPEUTICS INC PIPELINE, H1 2018
3.11 NEURIM PHARMACEUTICALS LTD PIPELINE, H1 2018
3.12 NICOX SA PIPELINE, H1 2018
3.13 OCULAR THERAPEUTIX INC PIPELINE, H1 2018
3.14 PEREGRINE OPHTHALMIC PIPELINE, H1 2018
3.15 SANTEN PHARMACEUTICAL CO LTD PIPELINE, H1 2018
3.16 SENJU PHARMACEUTICAL CO.,LTD PIPELINE, H1 2018
3.17 SHIRE PLC PIPELINE, H1 2018
3.18 SYLENTIS SAU PIPELINE, H1 2018
3.19 TAEJOON PHARMACEUTICAL CO., LTD. PIPELINE, H1 2018
3.20 VISCI LTD. PIPELINE, H1 2018
4 OCULAR HYPERTENSION DRUG SNAPSHOTS
4.1 ROCLATAN DRUG DETAILS
4.1.1 Snapshot-
4.1.2 Drug Overview-
4.1.3 Mechanism of Action-
4.1.4 Current Status-
4.1.5 Phase 3 Details
4.1.6 Trial details include-
4.2 MGV354 DRUG DETAILS
4.2.1 Snapshot-
4.2.2 Drug Overview
4.2.3 Mechanism of Action
4.2.4 Current Status
4.3 BIMATOPROST OCULAR INSERT
4.3.1 Snapshot-
4.3.2 Drug overview
4.3.3 Mechanism of Action
4.3.4 Phase 1/ 2 trial details
4.4 CF 101 DRUG DETAILS
4.4.1 Snapshot-
4.4.2 Drug Overview
4.4.3 Mechanism of Action
4.4.4 Current Status
4.4.5 Trial Details
4.5 WP-1303 DRUG DETAILS
4.5.1 Snapshot-
4.5.2 Drug Overview
4.5.3 Mechanism of Action
4.5.4 Current Status
4.5.5 Trial Details
4.6 ENV515 DRUG DETAILS
4.6.1 Snapshot-
4.6.2 Drug Overview
4.6.3 Mechanism of Action
4.6.4 Current Status
4.6.5 Trial Details
4.7 RG 7945- DRUG DETAILS
4.7.1 Snapshot-
4.7.2 Drug Overview
4.7.3 Mechanism of Action
4.7.4 Current Status
4.7.5 Phase 1 trial details
4.8 IWP 953 DRUG DETAILS
4.8.1 Snapshot-
4.8.2 Drug Overview
4.8.3 Mechanism of Action
4.8.4 Current Status
4.8.5 Trial details
4.9 SOPH067 DRUG DETAILS
4.9.1 Snapshot-
4.9.2 Drug Overview
4.9.3 Mechanism of Action
4.9.4 Current Status
4.9.5 Phase 3 Trial details
4.10 PRO-122 DRUG DETAILS
4.10.1 Snapshot-
4.10.2 Drug Overview
4.10.3 Mechanism of Action
4.10.4 Current Status
4.10.5 Trial details
4.11 PIROMELATINE DRUG DETAILS
4.11.1 Snapshot-
4.11.2 Drug Overview
4.11.3 Mechanism of Action
4.11.4 Current Status
4.11.5 Trial details
4.12 NCX 470 DRUG DETAILS
4.12.1 Snapshot-
4.12.2 Drug Overview
4.12.3 Mechanism of Action
4.12.4 Current Status
4.12.5 Trial Details
4.13 NCX 667 DRUG DETAILS
4.13.1 Snapshot-
4.13.2 Drug Overview
4.13.3 Mechanism of Action
4.13.4 Current Status
4.13.5 Trial details
4.14 NCX 1653 DRUG DETAILS
4.14.1 Snapshot-
4.14.2 Drug Overview
4.14.3 Mechanism of Action
4.14.4 Current Status
4.15 OTX-TP DRUG DETAILS
4.15.1 Snapshot-
4.15.2 Drug Overview
4.15.3 Mechanism of Action
4.15.4 Current Status
4.15.5 Trial details
4.16 OTX-TIC DRUG DETAILS
4.16.1 Snapshot-
4.16.2 Drug Overview
4.16.3 Mechanism of Action
4.16.4 Current Status
4.16.5 Trial Details
4.17 DE-117 DRUG DETAILS
4.17.1 Snapshot-
4.17.2 Drug Overview
4.17.3 Mechanism of Action
4.17.4 Current Status
4.17.5 Trial details
4.18 DE 126 DRUG DETAILS
4.18.1 Snapshot-
4.18.2 Drug Overview
4.18.3 Mechanism of Action
4.18.4 Current Status
4.18.5 Trial details
4.19 DE-130A DRUG DETAILS
4.19.1 Snapshot-
4.19.2 Drug Overview
4.19.3 Mechanism of Action
4.19.4 Current Status
4.20 Y-39983 DRUG DETAILS
4.20.1 Snapshot-
4.20.2 Drug Overview
4.20.3 Mechanism of Action
4.20.4 Current Status
4.20.5 Trial details
4.21 SJP 0135 DRUG DETAILS
4.21.1 Snapshot-
4.21.2 Drug Overview
4.21.3 Mechanism of Action
4.21.4 Current Status
4.21.5 Trial details
4.22 SHP 639 DRUG DETAILS
4.22.1 Snapshot-
4.22.2 Drug Overview
4.22.3 Mechanism of Action
4.22.4 Current Status
4.22.5 Trial details
4.23 BAMOSIRAN DRUG DETAILS
4.23.1 Snapshot-
4.23.2 Drug Overview
4.23.3 Mechanism of Action
4.23.4 Current Status
4.23.5 Trial details
4.24 LATANOPROST-PPDS DRUG DETAILS
4.24.1 Snapshot-
4.24.2 Drug Overview
4.24.3 Mechanism of Action
4.24.4 Current Status
4.24.5 Trial Details
4.25 VS 101 DRUG DETAILS
4.25.1 Snapshot-
4.25.2 Drug Overview
4.25.3 Mechanism of Action
4.25.4 Current Status
4.26 LIPOSOMAL LATANOPROST DRUG DETAILS
4.26.1 Snapshot-
4.26.2 Drug Overview
4.26.3 Mechanism of Action
4.26.4 Current Status
4.26.5 Trial details
4.27 TJO 002 DRUG DETAILS
4.27.1 Snapshot-
4.27.2 Drug Overview
4.27.3 Current status
4.27.4 Trial details
5 RECENT DEVELOPMENTS IN OCULAR HYPERTENSION PIPELINE
5.1 FDA APPROVES LATANOPROSTENE BUNOD OPHTHALMIC SOLUTION 0.024% - NOVEMBER 2017
5.2 DAILY USE OF STEROID DROPS INCREASES RISK FOR OCULAR HYPERTENSION - JULY 2017
5.3 NICOX PROVIDES CLINICAL AND REGULATORY UPDATE FOR NCX 470 FOR IOP LOWERING- JANUARY 2017
6 APPENDIX
6.1 ABOUT VPA RESEARCH
6.2 SOURCES AND RESEARCH METHODOLOGY
LIST OF FIGURES
Figure 1: Ocular Hypertension Pipeline by Phase, H1- 2018
Figure 2: Ocular Hypertension Pipeline by Companies, H1- 2018
Figure 3: Company wise Pipeline Drug Phases, H1- 2018
Figure 4: Ocular Hypertension Pipeline by Mechanism of Action, H1- 2018
Figure 5: Mechanism wise Pipeline Drug Phases, H1- 2018
Figure 1: Ocular Hypertension Pipeline by Phase, H1- 2018
Figure 2: Ocular Hypertension Pipeline by Companies, H1- 2018
Figure 3: Company wise Pipeline Drug Phases, H1- 2018
Figure 4: Ocular Hypertension Pipeline by Mechanism of Action, H1- 2018
Figure 5: Mechanism wise Pipeline Drug Phases, H1- 2018
LIST OF TABLES
Table 1: Ocular Hypertension Pipeline by Phase, H1- 2018
Table 2: Ocular Hypertension Pipeline by Companies, H1- 2018
Table 3: Ocular Hypertension Pipeline by Mechanism of Action, H1- 2018
Table 4: Aerie Pharmaceuticals, Inc - Ocular Hypertension Pipeline, H1- 2018
Table 5: Alcon Laboratories Inc - Ocular Hypertension Pipeline, H1- 2018
Table 6: Allergan Plc - Ocular Hypertension Pipeline, H1- 2018
Table 7: Can-Fite BioPharma Ltd - Ocular Hypertension Pipeline, H1- 2018
Table 8: D. Western Therapeutics Institute Inc - Ocular Hypertension Pipeline, H1- 2018
Table 9: Envisia Therapeutics Inc - Ocular Hypertension Pipeline, H1- 2018
Table 10: F. Hoffmann-La Roche Ltd- Ocular Hypertension Pipeline, H1- 2018
Table 11: Ironwood Pharmaceuticals Inc- Ocular Hypertension Pipeline, H1- 2018
Table 12: Laboratorios Sophia S.A. De C.V- Ocular Hypertension Pipeline, H1- 2018
Table 13: Mati Therapeutics Inc - Ocular Hypertension Pipeline, H1- 2018
Table 14: Neurim Pharmaceuticals Ltd - Ocular Hypertension Pipeline, H1- 2018
Table 15: NicOx SA - Ocular Hypertension Pipeline, H1- 2018
Table 16: Ocular Therapeutix Inc - Ocular Hypertension Pipeline, H1- 2018
Table 17: Peregrine Ophthalmic - Ocular Hypertension Pipeline, H1- 2018
Table 18: Santen Pharmaceutical Co Ltd - Ocular Hypertension Pipeline, H1- 2018
Table 19: SENJU Pharmaceutical Co.,Ltd - Ocular Hypertension Pipeline, H1- 2018
Table 20: Shire Plc - Ocular Hypertension Pipeline, H1- 2018
Table 21: Sylentis SAU - Ocular Hypertension Pipeline, H1- 2018
Table 22: Taejoon Pharmaceutical Co., Ltd.- Ocular Hypertension Pipeline, H1- 2018
Table 23: ViSci Ltd. - Ocular Hypertension Pipeline, H1- 2018
Table 1: Ocular Hypertension Pipeline by Phase, H1- 2018
Table 2: Ocular Hypertension Pipeline by Companies, H1- 2018
Table 3: Ocular Hypertension Pipeline by Mechanism of Action, H1- 2018
Table 4: Aerie Pharmaceuticals, Inc - Ocular Hypertension Pipeline, H1- 2018
Table 5: Alcon Laboratories Inc - Ocular Hypertension Pipeline, H1- 2018
Table 6: Allergan Plc - Ocular Hypertension Pipeline, H1- 2018
Table 7: Can-Fite BioPharma Ltd - Ocular Hypertension Pipeline, H1- 2018
Table 8: D. Western Therapeutics Institute Inc - Ocular Hypertension Pipeline, H1- 2018
Table 9: Envisia Therapeutics Inc - Ocular Hypertension Pipeline, H1- 2018
Table 10: F. Hoffmann-La Roche Ltd- Ocular Hypertension Pipeline, H1- 2018
Table 11: Ironwood Pharmaceuticals Inc- Ocular Hypertension Pipeline, H1- 2018
Table 12: Laboratorios Sophia S.A. De C.V- Ocular Hypertension Pipeline, H1- 2018
Table 13: Mati Therapeutics Inc - Ocular Hypertension Pipeline, H1- 2018
Table 14: Neurim Pharmaceuticals Ltd - Ocular Hypertension Pipeline, H1- 2018
Table 15: NicOx SA - Ocular Hypertension Pipeline, H1- 2018
Table 16: Ocular Therapeutix Inc - Ocular Hypertension Pipeline, H1- 2018
Table 17: Peregrine Ophthalmic - Ocular Hypertension Pipeline, H1- 2018
Table 18: Santen Pharmaceutical Co Ltd - Ocular Hypertension Pipeline, H1- 2018
Table 19: SENJU Pharmaceutical Co.,Ltd - Ocular Hypertension Pipeline, H1- 2018
Table 20: Shire Plc - Ocular Hypertension Pipeline, H1- 2018
Table 21: Sylentis SAU - Ocular Hypertension Pipeline, H1- 2018
Table 22: Taejoon Pharmaceutical Co., Ltd.- Ocular Hypertension Pipeline, H1- 2018
Table 23: ViSci Ltd. - Ocular Hypertension Pipeline, H1- 2018
